Ajanta Pharma Is A Compelling Investment Argument: ICICI Direct

Initiating Coverage Report On Ajanta Pharma By ICICI-Direct

Ajanta Pharma (APL) is a midcap pharma company with its focus on a few emerging markets in the export space and a few therapies in the domestic space. Adopting a slightly unconventional approach of not following the time-tested business models, the company has come a long way by demonstrating stand-out performances and handsome wealth creation for shareholders. In the quest for new product launches, backed by strong R&D support and management vision, the so called ‘differentiated approach’ has helped APL to carve out its own niche in the crowded midcap pharma space. We are initiating coverage on Ajanta Pharma as the company offers a unique proposition in the midcap pharma space with its self defined growth path.

AjantaPharma_IDirect_220914